Cerevance has expanded its Series B funding round with an additional close of $51 million, bringing the total to $116 million. The financing will support upcoming clinical trials focused on Parkinson’s disease, Amyotrophic Lateral Sclerosis (ALS), and schizophrenia. “We are thrilled to secure additional funding from world-class investors who strongly support the need for novel […]
Menu ≡ ╳ 
